

CITATION REPORT

List of articles citing

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

DOI: 10.1093/annonc/mdy326

Annals of Oncology, 2018, 29, 2076-2084.

Source: <https://exaly.com/paper-pdf/71618012/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
64	Tuning the Tumor Myeloid Microenvironment to Fight Cancer. <i>Frontiers in Immunology</i> , 2019 , 10, 1611	8.4	53
63	Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. <i>Lung Cancer</i> , 2019 , 134, 121-126	5.9	1
62	TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes. <i>EBioMedicine</i> , 2019 , 45, 328-340	8.8	12
61	Lipid nanoparticles of Type-A CpG D35 suppress tumor growth by changing tumor immune-microenvironment and activate CD8 T cells in mice. <i>Journal of Controlled Release</i> , 2019 , 313, 106-119	11.7	20
60	Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors. <i>OncImmunity</i> , 2019 , 8, e1659096	7.2	11
59	Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer. <i>Cancers</i> , 2019 , 11,	6.6	40
58	Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection. <i>Clinical Cancer Research</i> , 2019 , 25, 6283-6294	12.9	24
57	Molecular links between COPD and lung cancer: new targets for drug discovery?. <i>Expert Opinion on Therapeutic Targets</i> , 2019 , 23, 539-553	6.4	24
56	2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 768-783	8.9	24
55	Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals. <i>Aids</i> , 2019 , 33, 1315-1325	3.25	36
54	In Search of the Long-Desired Copernican Therapeutic Revolution in Small-Cell Lung Cancer. <i>Drugs</i> , 2020 , 80, 241-262	12.1	5
53	Immune profiling before treatment is predictive of TLR9-induced antitumor efficacy. <i>Biomaterials</i> , 2020 , 263, 120379	15.6	
52	Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC). <i>Frontiers in Oncology</i> , 2020 , 10, 1074	5.3	33
51	Toll-Like Receptor 9 Agonists in Cancer. <i>OncoTargets and Therapy</i> , 2020 , 13, 10039-10060	4.4	25
50	Plasmacytoid dendritic cells cross-prime naive CD8 T cells by transferring antigen to conventional dendritic cells through exosomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 23730-23741	11.5	23
49	Immunotherapy in Small Cell Lung Cancer. <i>Cancers</i> , 2020 , 12,	6.6	19
48	Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma. <i>Theranostics</i> , 2020 , 10, 6530-6543	12.1	11

47	Pulmonary Delivery of Nanoparticle-Bound Toll-like Receptor 9 Agonist for the Treatment of Metastatic Lung Cancer. <i>ACS Nano</i> , 2020 , 14, 7200-7215	16.7	13
46	Lipid-Mediated Insertion of Toll-Like Receptor (TLR) Ligands for Facile Immune Cell Engineering. <i>Frontiers in Immunology</i> , 2020 , 11, 560	8.4	1
45	Immune cell infiltration features and related marker genes in lung cancer based on single-cell RNA-seq. <i>Clinical and Translational Oncology</i> , 2021 , 23, 405-417	3.6	12
44	The benefits of etoposide capsules as maintenance therapy for patients with extensive-stage small cell lung cancer: a prospective two-stage, two-center study. <i>Journal of Thoracic Disease</i> , 2021 , 13, 343-352	2.6	0
43	Front Line Applications and Future Directions of Immunotherapy in Small-Cell Lung Cancer. <i>Cancers</i> , 2021 , 13,	6.6	3
42	Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity. <i>Clinical Cancer Research</i> , 2021 , 27, 3818-3824	12.9	1
41	Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 841-851	3.5	1
40	Role of Atypical Chemokines and Chemokine Receptors Pathways in the Pathogenesis of COPD. <i>Current Medicinal Chemistry</i> , 2021 , 28, 2577-2653	4.3	7
39	Immunotherapies targeting stimulatory pathways and beyond. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 78	22.4	9
38	Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021 , 12, 650486	8.4	3
37	The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021 , 8, 529-543	5.3	1
36	Immunotherapy in small cell lung cancer: one step at a time: a narrative review. <i>Translational Lung Cancer Research</i> , 2021 , 10, 2970-2987	4.4	1
35	DC-Derived Exosomes for Cancer Immunotherapy. <i>Cancers</i> , 2021 , 13,	6.6	8
34	Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer. <i>Thoracic Cancer</i> , 2021 , 12, 2732-2739	3.2	1
33	Toll-Like Receptor 9 Expression Levels in Breast Carcinoma Correlate with Improved Overall Survival in Patients Treated with Neoadjuvant Chemotherapy and Could Serve as a Prognostic Marker. <i>Genetic Testing and Molecular Biomarkers</i> , 2021 , 25, 12-19	1.6	
32	Lipid-mediated insertion of Toll-like receptor (TLR) ligands for facile immune cell engineering.		1
31	Advances and challenges in immunotherapy of small cell lung cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020 , 32, 115-128	3.8	9
30	Toll-like Receptor 9 in breast carcinoma is a good prognostic marker in patients treated with neoadjuvant chemotherapy.		

29 Immunology and immunotherapy in CRC. **2022**, 435-453

28 Immunology and Immunotherapy of Colorectal Cancer. **2020**, 261-289

27 Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies.. *Current Oncology*, **2021**, 28, 4894-4928 2.8

26 Plasmacytoid Dendritic Cells and Cancer Immunotherapy.. *Cells*, **2022**, 11,

7.9 0

25 Development and validation of radiomics nomograms for preoperative prediction of characteristics in non-small cell lung cancer and circulating tumor cells.

24 Therapeutic modalities in small cell lung cancer: a paradigm shift after decades of quiescence.. *Expert Opinion on Pharmacotherapy*, **2022**, 1-15

4

23 Type I interferon-mediated tumor immunity and its role in immunotherapy.. *Cellular and Molecular Life Sciences*, **2022**, 79, 191

10.3 2

22 CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials.. *Pharmaceutics*, **2021**, 14,

6.4 1

21 SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs.. *Frontiers in Oncology*, **2022**, 12, 840783

5.3 0

20 Image_1.TIF. **2020**,

19 Image_2.TIF. **2020**,

18 Image_3.TIF. **2020**,

17 Image_4.TIF. **2020**,

16 Image_5.TIF. **2020**,

15 Image_6.TIF. **2020**,

14 Image_7.tif. **2020**,

13 Image_8.TIF. **2020**,

12 Image_9.TIF. **2020**,

11 Table_1.XLSX. 2020,

10	Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity.. <i>Cancer Treatment and Research</i> , 2022, 183, 91-129	3.5	0
9	Targeting tumor-associated macrophages for cancer treatment. <i>Cell and Bioscience</i> , 2022, 12,	9.8	1
8	Aging-associated accumulation of mitochondrial DNA mutations in tumor origin.		1
7	Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities. 1-26		3
6	Identification of the effects of COVID-19 on patients with pulmonary fibrosis and lung cancer: a bioinformatics analysis and literature review. 2022, 12,		1
5	Bibliometric analysis of global research trends on small-cell lung cancer (2012-2021). 12,		0
4	Understanding the role of Toll-like receptors in lung cancer immunity and immunotherapy. 13,		0
3	Toll-like receptor-targeted anti-tumor therapies: Advances and challenges. 13,		0
2	Promises and challenges for targeting the immunological players in the tumor micro-environment □ Critical determinants for NP-based therapy. 2023, 10, 100134		0
1	Pre-Induced ICD Membrane-Coated Carrier-Free Nanoparticles for the Personalized Lung Cancer Immunotherapy. 2201569		0